Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus

被引：0
|
作者：
Heise, T. [1 ]
Haahr, H. [2 ]
Jensen, L. [2 ]
Erichsen, L. [2 ]
Hompesch, M. [3 ]
机构：
[1] Profil, Neuss, Germany
[2] Novo Nordisk AS, Soborg, Denmark
[3] Profil Inst Clin Res Inc, Chula Vista, CA USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
120
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [21] Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
    Zijlstra, Eric
    Demissie, Marek
    Graungaard, Tina
    Heise, Tim
    Nosek, Leszek
    Bode, Bruce W.
    CLINICAL ENDOCRINOLOGY, 2017, 86 : 46 - 46
  • [22] HIGHER EARLY INSULIN EXPOSURE AND GREATER EARLY GLUCOSE-LOWERING EFFECT WITH FASTER-ACTING INSULIN ASPART IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Haahr, H.
    Hoevelmann, U.
    Brondsted, L.
    Adrian, C. L.
    Nosek, L.
    Heise, T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A42 - A42
  • [23] Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart in patients with type 1 diabetes mellitus
    Haahr, H.
    Hoevelmann, U.
    Brondsted, L.
    Adrian, C. L.
    Nosek, L.
    Heise, T.
    DIABETOLOGIA, 2014, 57 : S382 - S383
  • [24] Copenfast trial: foetal growth and glycaemic control in pregnant women with type 1 or type 2 diabetes randomised to faster-acting insulin aspart or insulin aspart
    Norgaard, S.
    Soholm, J.
    Mathiesen, E.
    Norgaard, K.
    Clausen, T.
    Holmager, P.
    Do, N.
    Damm, P.
    Ringholm, L.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S122 - S122
  • [25] Postprandial glucose control using the Medtronic Advanced Hybrid Closed Loop System: faster-acting insulin aspart vs insulin aspart
    Lee, M. H.
    Vogrin, S.
    Paldus, B.
    Morrison, D.
    Zaharieva, D.
    Lu, J.
    Jones, H.
    Netzer, E.
    Sims, C.
    MacIsaac, R. J.
    Grosman, B.
    Roy, A.
    Kurtz, N.
    Jenkins, A.
    O'Neal, D. N.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S328 - S328
  • [26] Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal-bolus improves glycaemic control in Type 1 diabetes: the onset 1 trial
    Russell-Jones, D.
    Bode, B. W.
    De Block, C.
    Franek, E.
    Heller, S.
    Mathieu, C.
    Philis-Tsimikas, A.
    Rose, L.
    Woo, V.
    Osterskov, A. B.
    Graungaard, T.
    Bergenstal, R.
    DIABETIC MEDICINE, 2017, 34 : 8 - 8
  • [27] Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes
    Heise, Tim
    Pieber, Thomas R.
    Danne, Thomas
    Erichsen, Lars
    Haahr, Hanne
    DIABETES, 2016, 65 : A239 - A239
  • [28] Faster-acting insulin aspart vs insulin aspart as part of basal-bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial
    Saravanan, P.
    Bowering, K.
    Case, C.
    Harvey, J.
    Reeves, M.
    Sampson, M.
    Strzinek, R.
    Bretler, D. M.
    Bang, R. B.
    Bode, B. W.
    DIABETIC MEDICINE, 2017, 34 : 21 - 21
  • [29] Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial
    Heise, Tim
    Zijlstra, Eric
    Nosek, Leszek
    Rikte, Tord
    Haahr, Hanne
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 208 - 215
  • [30] Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
    Haahr, Hanne
    Pieber, Thomas R.
    Mathieu, Chantal
    Gondolf, Theis
    Shiramoto, Masanari
    Erichsen, Lars
    Heise, Tim
    CLINICAL PHARMACOKINETICS, 2019, 58 (05) : 639 - 649
12345